Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Bladder cancer

Exceptional responder to everolimus identified

Nature Reviews Urology volume 11, page 244 (2014)Cite this article

Subjects

Exceptional responders are patients who experience a complete or partial response to treatment for ≥6 months, in a clinical trial in which <10% of patients respond. One such patient with bladder cancer has been identified in a phase I trial of everolimus and pazopanib, demonstrating a complete radiographic response for 14 months. Whole-exome sequencing revealed two activating mutations in mTOR, which might explain the patient's heightened sensitivity to everolimus. Other patients with such mutations might be selected to receive everolimus therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wagle, N. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 10.1158/2159-8290.CD-13-0353

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Exceptional responder to everolimus identified. Nat Rev Urol 11, 244 (2014). https://doi.org/10.1038/nrurol.2014.78

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2014.78

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing